Funda I-BELVIQ Ngaphandle Kwomshuwalense
I-BELVIQ (i-lorcaserin) imithi yokulahlekelwa isisindo evunyelwe yi-Food and Drug Administration (FDA). Uma ukhuluphele ngokweqile noma ukhuluphele ngokweqile futhi ube nesimo sezokwelapha ezihlobene nesisindo, kungakusiza ukuba ulahlekelwe isisindo. Kodwa imiphumela emibi ye-BELVIQ futhi izindleko ze-BELVIQ kufanele zicutshangelwe ngaphambi kokuba unqume ukuthi iphilisi lokudla likulungele yini.
Indlela i-BELVIQ isebenza ngayo
I-BELVIQ ne-BELVIQ XR (ukukhululwa okukhulisiwe) yi-FDA-evunyelwe ukusetshenziswa kubantu abadala abane-BMI engama-30 nangaphezulu, noma kubantu abane- mass mass index okungenani engu-27 futhi okungenani banezimo ezihlobene nesisindo esisodwa njengegazi eliphezulu ukucindezelwa, uhlobo lwesifo sikashukela sesi-2, noma i-cholesterol ephezulu.
I-BELVIQ iklanyelwe ukukusiza uzizwe ugcwele ngemuva kokuthi udle ukudla okuncane. Imithi ivuselela i-serotonin receptors ebuchosheni bakho. I-serotonin receptors ilawula ukulamba. Uma bekhombisa ukuthi umzimba wakho uzizwa ugcwele, ungase ukwazi ukudla kancane futhi ulahlekelwe isisindo.
Ukubeka ulwazi nge-BELVIQ kuchaza ukuthi abasebenzisi bathatha iphilisi elilodwa le-10 milligram ngosuku ngalunye kanye nokudla okuphansi kwekhalori nokuzivocavoca. Ngokusho kwe-FDA, lesi sidakamizwa kufanele sithathwe impilo yonke yesiguli ukuze silondoloze isisindo esinempilo . I-BELVIQ akufanele ithathwe ngabesifazane abakhulelwe noma abancancisayo.
Ngingakanani Ukugqoka Engizoyeka Ku-BELVIQ?
Ekuvivinyweni kwemitholampilo, abacwaningi bacwaninga iziguli ezingu-8000 nezikhulu kakhulu. Isilinganiso sesisindo esilahlekile phakathi kwalezi zihloko zokuhlolwa kwaba ngu-3 kuya ku-3.7% wesisindo somzimba sabo sonke. Iziguli ezingaba ngu-47% ezingenaso isifo sikashukela zilahlekelwe okungenani u-5% wesisindo somzimba wazo, uma kuqhathaniswa neziguli ezingu-23% ezithatha i-placebo.
Ngakho-ke, uma okwamanje ulinganisa amakhilogremu angu-250, kungaba kuhle ukulindela ukulahlekelwa phakathi kwamakhilogremu angu-7.5 no-12.5 ngenkathi uthatha i-BELVIQ ngokudla nokuzivocavoca. Nakuba lokhu kungase kungabonakali njengokulahlekelwa kwesisindo esikhulu, ezinye iziguli zingase zithole izinzuzo zezempilo ngokulahlekelwa isisindo esincane.
I-Centers for Disease Control iphawula ukuthi ukulahlekelwa isisindo somzimba wakho u-5 kuya ku-10 kuphela kunganikeza izinzuzo zezempilo ezifana nokuthuthukiswa komfutho wegazi, i-cholesterol yegazi, kanye noshukela egazini.
Uma ungalahlekelwa okungenani u-5% wesisindo somzimba wakho emasontweni angu-12 okuqala ku-BELVIQ, akunakwenzeka ukuthi izidakamizwa zizokusebenzela, futhi udokotela wakho angakukhipha imithi.
I-BELVIQ Imiphumela emibi kanye nezingozi
Ngokusho kwe-FDA, imiphumela emibi ejwayelekile ye-BELVIQ ihlanganisa ikhanda, isizungu, ukukhathala, isisindo sokugcoba, umlomo omile, nokuqothulwa. Ezigulini zesifo sikashukela, imiphumela emibi yi-sugar ephansi yegazi (i-hypoglycemia), ikhanda lomlomo, ubuhlungu bokubuyela emuva, ukukhwehlela nokukhathala. I-Institutes of Health kazwelonke inikeza uhlu olugcwele lwemiphumela emibi okufanele uhlolisise futhi uxoxe nodokotela wakho ngaphambi kokuba uthathe imithi. Lesi sidakamizwa asivunyelwanga neziguli eziye zathola ukusabela ku-lorcaserin noma kunoma yiziphi izingxenye zomkhiqizo esikhathini esidlule.
Ekuqaleni kokuhlolwa, abacwaningi babekhathazekile ngezinkinga zenhliziyo ezigulini ezithatha i-BELVIQ. Kodwa i-FDA isuqedile ukuthi lesi sidakamizwa asinakwenzeka ukuba kubangele izinkinga ze-valve zenhliziyo ezazikhishwa ezikoleni zokuqala. Kodwa-ke, i-BELVIQ ayizange isetshenziswe ezigulini ezinesifo se-valvular senhliziyo enkulu kanti i-FDA incoma ukuthi iziguli ezinenkinga ye-heart congestive ziqaphe ngokukhethekile uma zithatha imithi.
Ngaphezu kwalokho, ngokusho kwe- New England Journal of Medicine kukhona ukukhathazeka ukuthi lesi sidakamizwa singase sithwale ingozi yezifo zengqondo noma ezingokwengqondo, ikakhulukazi kubantu abaphuza imithi ethile. Ngokusho kwe-FDA, abasebenzisi be-BELVIQ bangase bahlanganise nesifo se-serotonin, ikakhulukazi uma kuthathwe imithi ekwandisa amazinga we-serotonin noma isebenzise ama-serotonin receptors. Lezi zihlanganisa imithi esetshenziselwa ukuphatha ukucindezeleka kanye nekhanda le-migraine. I-Lorcaserin ingase ibangele ukuphazamiseka ekunakekeleni noma kwimemori.
I-Belviq Izindleko Nemishuwalense
Uma ubala izindleko zakho eziphelele ze-BELVIQ, kuzomele uhlale ukhumbule ukuthi umthamo ngokwama-FDA yimiphilisi emibili ngosuku.
Ngakho iziguli eziningi zizodinga amaphilisi angama-60 ngenyanga. Kumele futhi ukhumbule ukuthi uma ufuna ukugcina ukulahlekelwa kwesisindo sakho kudingeka uhlale ku-BELVIQ futhi, eqinisweni, uqhubeke ukhokhela imithi.
Intengo ye-BELVIQ ibuye ihluke ngokusekelwe emshuwalense kanye nephilisi oyithathayo (i-BELVIQ noma i-BELVIQ XR). Uma unomshuwalense wezokwelapha ohlanganisa izindleko zemithi, khona-ke izindleko zakho ezijwayelekile ngosuku zizogijima nge $ 2 ngosuku nge-BELVIQ XR no-$ 2.20 ngosuku nge-BELVIQ ngamakhadi okugcina imali atholakala kwiwebhusayithi yezinkampani.
Uma ungenayo umshwalense wemithi yomuthi, ungalindela ukukhokha ngaphezulu. Izindleko ezilinganiselwe ze-BELVIQ ngaphandle kokusizwa zisondele ku-$ 3.20 ngosuku.
Ingabe i-BELVIQ Ikulungile?
Le mithi yokudla ayikhuthazwa "ukulahlekelwa isisindo esingenalutho." Okokuthi, iphilisi lokudla akufanele lisetshenziselwe abantu abafuna nje ukubheka kangcono ku-jeans yabo eyintandokazi. Ngokuqinisekile, kunezindleko ezibalulekile okufanele zicatshangelwe uma unesithakazelo ekuthatheni i-BELVIQ. Izibuyekezo eziningana ezibucayi ze-BELVIQ zikhulume ngohlu olude lwemiphumela emibi kanye nesisindo esincane esingakusiza ukuba ulahlekelwe. Kodwa uma uke wazama ezinye izindlela zokulahlekelwa isisindo ngaphandle kokuphumelela, ungase uthande ukuxoxa no-BELVIQ nodokotela wakho. Qinisekisa ukuthi ulinganisa zonke izingozi nezinzuzo uma ukhuluma nomhlinzeki wakho wokunakekelwa kwezempilo ukuze wenze isinqumo esingcono kakhulu sezokwelapha nokuphila kwakho.
Imithombo:
> Arena Pharmaceuticals . I-Arena Pharmaceuticals no-Eisai Yenza i-FDA Imvume ye-BELVIQ® (i-lorcaserin HCl) ye-Chronicle Weight Management kuBantu abadala abangaphezu kokukhululeka okune-Comorbidity or Obese.
Izikhungo zokuLawula izifo. Ukulinganisa okunempilo - akuyona ukudla, kuyindlela yokuphila! http://www.cdc.gov/healthyweight/losing_weight/index.html
Eric Colman, MD, Julie Golden, MD, Mary Roberts, MD, Amy Egan, MD, MPH, Joyce Weaver, Pharm.D., NoC Curtis Rosebraugh, MD, MPH. "Ukuhlolwa kwe-FDA yezidakamizwa ezimbili zokuphathwa kwe-Weight Management." I-New England Journal of Medicine Okthoba 25, 2012.
Ukuphathwa Kwezokudla Nezidakamizwa. Imithi Ihlose Ukulawula Isisindo Sesikhathi Eside. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm312380.htm
Ukuphathwa Kwezokudla Nezidakamizwa. I-FDA ivumela uBelviq ukuthi aphathe abantu abadala abakhuluphele ngokweqile noma abakhuluphele. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm
Ukufuna i-Alpha. Ukuhlola i-Belviq ye-Arena njengesidakamizwa se-Diabesity. http://seekingalpha.com/article/1059621-singa-arenas-belviq-as-a-diabesity-drug